Search results for "COMB"

showing 10 items of 7115 documents

Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits

2003

Objective— The effects of combined expression of human hepatic lipase (HL) and human apolipoprotein B (apoB) on low-density lipoprotein (LDL) subclasses were examined in rabbits, a species naturally deficient in HL activity. Methods and Results— In apoB-transgenic rabbit plasma, >80% of the protein was found in the 1.006- to 1.050-g/mL fraction. Gradient gel electrophoresis (GGE) of this fraction revealed two distinct species, designated large and small LDL. A denser fraction (d=1.050 to 1.063 g/mL) contained small LDL as well as another discrete LDL subspecies, designated very small LDL. Expression of HL resulted in reductions in protein concentrations in the 1.006- to 1.050-g/mL densi…

medicine.medical_specialtyApolipoprotein BRecombinant Fusion ProteinsTriacylglycerol lipaseAnimals Genetically ModifiedSpecies SpecificityInternal medicineCentrifugation Density GradientmedicineAnimalsHumansTriglyceridesApolipoproteins BGel electrophoresischemistry.chemical_classificationLagomorphabiologyLipasebiology.organism_classificationAnimal FeedSpecific Pathogen-Free OrganismsLipoproteins LDLMolecular WeightEndocrinologyEnzymechemistrybiology.proteinElectrophoresis Polyacrylamide GelFemalelipids (amino acids peptides and proteins)Density gradient ultracentrifugationRabbitsHepatic lipaseCardiology and Cardiovascular MedicineLipoprotein
researchProduct

Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)

2020

International audience; Background: Several guidelines dedicated to metastatic colorectal cancer (mCRC) are available. Since 2013 no recent guidelines are specifically dedicated to older patients and based on a systematic review. Materials and methods: A multidisciplinary Task Force with digestive oncologists, geriatricians and methodologists from the SoFOG was formed in 2016 to update recommendations on medical treatment of mCRC based on a systematic review of publications from 2000 to 2018. Search strategy has followed a standardized protocol from the formulation of clinical questions and definition of a search algorithm to the selection of complete articles for recommendations. Results: …

medicine.medical_specialtyBevacizumabColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Context (language use)Targeted therapyMetastasisMetastasisTargeted therapy03 medical and health scienceschemistry.chemical_compoundOlder patient0302 clinical medicineRegorafenibMedicineHumansChemotherapyNeoplasm MetastasisIntensive care medicineSocieties MedicalAgedNeoplasm StagingHepatologyPerformance statusbusiness.industryGastroenterologymedicine.diseaseCombined Modality TherapyColorectal cancer3. Good healthGeriatric oncologychemistry030220 oncology & carcinogenesisQuality of Life030211 gastroenterology & hepatologyFrancebusinessColorectal Neoplasmsmedicine.drug
researchProduct

The inhibitors - a challenge for the management of patients with hereditary haemophilia A.

2018

Abstract Introduction. Our research strategy was aimed at evaluating the possible implication of the type of factor VIII product administered as substitution treatment to haemophilia A patients in the occurrence of inhibitors and their consequences on the management. Methods. Scientific articles from July 2015 to July 2017 were searched using the PubMed and PubMed Central databases. The used search terms included “haemophilia A”, “inhibitors”, “plasma-derived factor VIII” and “recombinant factor VIII”. Results. The risk factors for inhibitors occurrence may be patients-related (genetic and nongenetic) and treatment-related. The possibility of a correlation between the increased purity of fa…

medicine.medical_specialtyBispecific antibodyHaemophilia A030204 cardiovascular system & hematologyBioinformaticsHemophilia AFactor VIII productRecombinant factor viii03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesinhibitorsmedicineHumansInternal medicineFactor VIIIbusiness.industryhaemophilia amedicine.diseaseplasma-derived factor viiiRC31-1245Recombinant Proteinsneutralizing alloantibodiesSearch termsCoagulationrecombinant factor viiibusiness030215 immunologyRomanian journal of internal medicine = Revue roumaine de medecine interne
researchProduct

Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group fo…

2000

Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

medicine.medical_specialtyBone marrow transplantPremedicationAntibodies ProtozoanBlood DonorsOpportunistic InfectionsImmunocompromised HostSeroepidemiologic StudiesInternal medicineTrimethoprim Sulfamethoxazole Drug CombinationEpidemiologymedicineAnimalsHumansTransplantation HomologousTransplantationMarrow transplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologymedicine.diseaseToxoplasmosisTransplantationHaematopoiesissurgical procedures operativeImmunologybusinessToxoplasmaDisease transmissionToxoplasmosisBone Marrow Transplantation
researchProduct

Severe Tremor After Cotrimoxazole-Induced Elevation of Venlafaxine Serum Concentrations in a Patient With Major Depressive Disorder

2013

: We describe a female patient who was an extensive metabolizer of cytochrome P450 isoenzyme (CYP) 2D6 and an intermediate metabolizer of CYP2C19 (genotype: CYP2C19 *1/*2). She exhibited high serum concentrations of venlafaxine and O-desmethylvenlafaxine and developed severe tremor after comedication with cotrimoxazole (sulfamethazole/trimethoprim). Venlafaxine is mainly metabolized by O- and N-demethylation. O-demethylation is catalyzed by the highly polymorphic CYP2D6 and N-demethylation by several enzymes, CYP2C19, CYP2C9, and CYP3A4. The observed overall pharmacokinetic effect was most probably the result of decreased N-demethylation of venlafaxine by (1) reduced expression of CYP2C19 d…

medicine.medical_specialtyCYP2D6Venlafaxine HydrochlorideVenlafaxineCYP2C19Severity of Illness IndexGastroenterologyAnti-Infective AgentsInternal medicineTremorTrimethoprim Sulfamethoxazole Drug CombinationHumansMedicineDrug InteractionsPharmacology (medical)PsychiatryCYP2C9PharmacologyDepressive Disorder MajorCYP3A4business.industryVenlafaxine HydrochlorideMiddle AgedCyclohexanolsmedicine.diseaseTrimethoprimCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Major depressive disorderFemaleAryl Hydrocarbon HydroxylasesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic Drug Monitoring
researchProduct

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A pros…

2015

We performed a multicenter study to validate the concept that a simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and to analyze potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria. One hundred and seventy-three patients aged > 69 treated with curative or palliative intent by clinical judgement only were grouped according to CGA into fit (46%), unfit (16%) and frail (38%) categories. Two-year overall survival (OS) was significantly better in fit than in non-fit patients (84% vs. 47%; p < 0.0001).…

medicine.medical_specialtyCancer ResearchMultivariate analysisLymphomaChemotherapeutic approaches; Immunotherapy; Lymphoma and Hodgkin disease; Hematology; Oncology; Cancer ResearchMEDLINEDisease-Free SurvivalInternal medicineComprehensive Assesment Diffuse large B cell lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicine80 and overLarge B-CellHumansProspective StudiesProspective cohort studyGeriatric AssessmentAgedAged 80 and overChemotherapeutic approachesbusiness.industryPalliative CareGeriatric assessmentHematologymedicine.diseasePrognosisDiffuseSurgeryLymphomaSettore MED/15 - MALATTIE DEL SANGUETreatment OutcomeMulticenter studyOncologyLymphoma and Hodgkin diseaseMultivariate AnalysisTreatment decision makingImmunotherapyLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the …

2013

Kast, Richard E. et al.

medicine.medical_specialtyCaptoprilTel avivMorpholinesArtesunateReviewGluconatesAngiotensinQuality of lifeAuranofinSertralineAntineoplastic Combined Chemotherapy ProtocolsDisulfiramTemozolomidemedicineRecurrent diseaseHumansIn patientNelfinavirTemozolomideBrain Neoplasmsbusiness.industrySuccinatesNeurokininCytotoxic chemotherapyUniversity hospitalmedicine.diseaseArtemisininsSurgeryDacarbazineKetoconazoleOncologyangiotensin aprepitant artesunate auranofin captopril cytokines disulfiram glioblastoma ketoconazole nelfinavir neurokinin sertraline temozolomideFamily medicineCytokinesNeoplasm Recurrence LocalGlioblastomabusinessAprepitantGlioblastomamedicine.drugOncotarget
researchProduct

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

2011

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in th…

medicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsPolymorphism Single NucleotideFlaviviridaeInternal medicineGenotypeEpidemiologyRibavirinmedicineHumansClinical Trials as TopicHepatologybiologybusiness.industryInterleukinsLiver Neoplasmsvirus diseasesHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsLiver TransplantationNatural historyHepatocellular carcinomaInterferon Type IPractice Guidelines as TopicHCVInterferonsbusiness
researchProduct

Special Considerations for Antihypertensive Agents in Dialysis Patients

2010

Hypertension is present in most patients with end-stage renal disease and likely contributes to the premature cardiovascular disease in dialysis patients. Previous practice guidelines have recommended that, in patients on chronic dialysis, blood pressure (BP) should be reduced below 130/80 mm Hg. This is based on opinions but not strong evidence, since no concrete information exists about which BP values should be the parameter to follow and which should be the target BP values. The majority of the antihypertensive agents can be used in this population, but the pharmacokinetics altered by the impaired kidney function and dialyzability influence the appropriate dosage as well as the time and…

medicine.medical_specialtyCardiotonic AgentsHypertension RenalCombination therapyMetabolic Clearance Ratemedicine.drug_classVasodilator Agentsmedicine.medical_treatmentAdrenergic beta-AntagonistsPopulationAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsRenal DialysisInternal medicinemedicineHumansDrug InteractionsDiureticseducationAntihypertensive drugAntihypertensive AgentsDialysisRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryHematologyGeneral MedicineCalcium Channel Blockersmedicine.diseaseEndocrinologyBlood pressureCardiovascular DiseasesNephrologyPractice Guidelines as TopicPolypharmacyKidney Failure ChronicDrug Therapy CombinationHemodialysisbusinessAngiotensin II Type 1 Receptor BlockersKidney diseaseBlood Purification
researchProduct

Hypolipidaemic effects of fenofibrate and fasting in the herbivorous grass carp (Ctenopharyngodon idella) fed a high-fat diet

2008

We investigated whether the hypolipidaemic effect of fenofibrate and fasting observed in most omnivorous mammals may also apply to herbivorous fish. Grass carp (Ctenopharyngodon idella) fed a high-fat (8 %) diet exhibited a marked increase in blood lipids and body fat after 6 weeks. They were then treated with fenofibrate (100 mg/kg body weight) in the same high-fat diet for 2 weeks, followed by fasting for 1 week. Plasma lipid concentration, body fat amount, fatty acid composition, plasma thiobarbituric acid-reactive substances and some parameters related to hepatic fatty acid oxidation were measured, and liver samples were stained for histological examination. Fenofibrate treatment decrea…

medicine.medical_specialtyCarpsmedicine.drug_classMedicine (miscellaneous)Blood lipidsHyperlipidemiasFibrateBiologyThiobarbituric Acid Reactive SubstancesLipid peroxidationFish Diseaseschemistry.chemical_compoundFenofibrateInternal medicinemedicineAnimalsBeta oxidationHypolipidemic AgentsNutrition and DieteticsFenofibrateCholesterolFatty AcidsLipid metabolismFastingLipid Metabolismbiology.organism_classificationCombined Modality TherapyDietary FatsGrass carpEndocrinologyLiverchemistryAnimal Nutritional Physiological Phenomenalipids (amino acids peptides and proteins)Lipid PeroxidationOxidation-Reductionmedicine.drugBritish Journal of Nutrition
researchProduct